Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis

Haiqing Ma, Huanhuan Sun, Xiaoping Sun, Haiqing Ma, Huanhuan Sun, Xiaoping Sun

Abstract

To evaluate treatment outcomes in children with acute lymphoblastic leukemia (ALL) over the past 3 decades, we assessed the survival of children with ALL in the Surveillance, Epidemiology, and End Results (SEER) database. Among 12,096 patients from 18 SEER sites diagnosed from 1981 to 2010, survival rates improved each decade from 74.8% to 84.5% to 88.6% at 5 years and from 69.3% to 80.9% to 85.5% at 10 years (P < 0.0001). For ages 10-14 years, 10-year survival increased by more than 20 percentage points to 75.3%, but for infants, it remained low at 54.7%. Improvements in survival rates were observed in both sexes, but survival rates were higher in girls than in boys. For ages 0-14 years during the 2001-2010 period, the 10-year relative survival rates were 87.8% in girls and 83.6% in boys (P < 0.01). Survival rates in child with ALL are expected to further improve with continuous advance in therapies such as targeted therapy and personalized therapy.

Figures

Figure 1. Trends in 10-year relative survival…
Figure 1. Trends in 10-year relative survival estimates for patients with acute lymphoblastic leukemia (ALL) from 18 SEER sites from 1981 to 2010.
Data are shown by age group (ages 0–14, 0, 1–4, 5–9, and 10–14 years) and calendar period over the 3 decades.
Figure 2. Trends in 10-year relative survival…
Figure 2. Trends in 10-year relative survival estimates for male (a) and female (b) patients with ALL from 18 SEER sites from 1981 to 2010.
Data are shown by age group (in years) and calendar period over the 3 decades.
Figure 3. 5-year and 10-year relative survival…
Figure 3. 5-year and 10-year relative survival estimates of patients with ALL aged 0–14 years from 18 SEER sites according to socioeconomic status/county level poverty rates (a), and race (b) over 3 decades, from 1981 to 2010.

References

    1. Siegel R., Naishadham D. & Jemal A. Cancer statistics, 2013. CA Cancer J Clin 63, 11–30 (2013).
    1. Hunger S. P. et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol 30, 1663–1669 (2012).
    1. Pui C. H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360, 2730–2741 (2009).
    1. Veerman A. J. et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol 10, 957–966 (2009).
    1. Salzer W. L. et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the Children's Oncology Group. Leukemia 24, 355–370 (2010).
    1. Gaynon P. S. et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children's Oncology Group Report. Leukemia 24, 285–297 (2010).
    1. Pui C. H. et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 24, 371–382 (2010).
    1. Moricke A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24, 265–284 (2010).
    1. Silverman L. B. et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 24, 320–334 (2010).
    1. Conter V. et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 24, 255–264 (2010).
    1. Kamps W. A. et al. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 24, 309–319 (2010).
    1. Mitchell C., Richards S., Harrison C. J. & Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001. Leukemia 24, 406–418 (2010).
    1. Pulte D., Gondos A. & Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990–2004. J Natl Cancer Inst 100, 1301–1309 (2008).
    1. Brenner H. & Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 164, 689–696 (2006).
    1. Brenner H. & Hakulinen T. Up-to-date estimates of cancer patient survival even with common latency in cancer registration. Cancer Epidemiol Biomarkers Prev 15, 1727–1732 (2006).
    1. Kroll M. E., Stiller C. A., Murphy M. F. & Carpenter L. M. Childhood leukaemia and socioeconomic status in England and Wales 1976–2005: evidence of higher incidence in relatively affluent communities persists over time. Br J Cancer 105, 1783–1787 (2011).
    1. Adam M., Rebholz C. E., Egger M., Zwahlen M. & Kuehni C. E. Childhood leukaemia and socioeconomic status: what is the evidence? Radiat Prot Dosimetry 132, 246–254 (2008).
    1. Poole C., Greenland S., Luetters C., Kelsey J. L. & Mezei G. Socioeconomic status and childhood leukaemia: a review. Int J Epidemiol 35, 370–384 (2006).
    1. Krieger N., Chen J. T., Waterman P. D., Rehkopf D. H. & Subramanian S. V. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures--the public health disparities geocoding project. Am J Public Health 93, 1655–1671 (2003).
    1. Krieger N. et al. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project. Am J Epidemiol 156, 471–482 (2002).
    1. Hijiya N. et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297, 1207–1215 (2007).
    1. Schmiegelow K. et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 31, 2469–2476 (2013).
    1. Inaba H., Greaves M. & Mullighan C. G. Acute lymphoblastic leukaemia. Lancet 381, 1943–1955 (2013).
    1. Surveillance, Epidemiology, and End Results (SEER) Program. Research data (1973–2010), . National Cancer Institute, Division of Cancer Control and Population Services, Surveillance Research Program, Surveillance Systems Branch, released April 2013 [accessed Nov 6, 2013].
    1. Singh G. K., Miller B. A., Hankey B. F. & Edwards B. K. Area Socioeconomic Variations In US Cancer Incidence, Mortality, Stage, Treatment, And Survival, 1975–1999. National Cancer Institute, Bethesda. Report No.: NIH Publication No. 03-5417. (2003).
    1. Dickman P. W. & Adami H. O. Interpreting trends in cancer patient survival. J Intern Med 260, 103–117 (2006).
    1. Hakulinen T., Seppa K. & Lambert P. C. Choosing the relative survival method for cancer survival estimation. Eur J Cancer 47, 2202–2210 (2011).

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi